| Drug Name |
Butabarbital |
| Drug ID |
BADD_D00319 |
| Description |
Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.[A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.[A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines.[A19735] Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980]
Butabarbital was granted FDA approval on 5 June 1939.[L13613] |
| Indications and Usage |
Butabarbital is indicated for use as a sedative or hypnotic.[L13613] Butabarbital should not be used to treat insomnia for longer than 2 weeks.[L13613] |
| Marketing Status |
approved; illicit |
| ATC Code |
Not Available |
| DrugBank ID |
DB00237
|
| KEGG ID |
D03180
|
| MeSH ID |
C084833
|
| PubChem ID |
2479
|
| TTD Drug ID |
D0A4JK
|
| NDC Product Code |
61960-2400 |
| UNII |
P0078O25A9
|
| Synonyms |
secbutabarbital | butabarbital | secumalum | butabarbitone | secbutobarbitone | Butisol Sodium | Butisol | Sarisol | secbutabarbital sodium | butabarbital sodium | 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylpropyl)-, monosodium salt |
